GOODWILL AND OTHER INTANGIBLE ASSETS

12 Months Ended

Oct. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2020 and 2021:


	Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total
	(in millions)
Goodwill as of October 31, 2019	$	1,438	$	1,594	$	561	$	3,593
Foreign currency translation impact	3		5		1		9

Goodwill as of October 31, 2020	$	1,441	$	1,599	$	562	$	3,602
Foreign currency translation impact	5		—		3		8
Goodwill arising from acquisitions and adjustments	—		365		—		365
Goodwill as of October 31, 2021	$	1,446	$	1,964	$	565	$	3,975

As of September 30, 2021, our annual impairment test date, we assessed goodwill for triggering events and circumstances, including impacts due to COVID-19, and determined no impairment of goodwill was indicated for our reporting units.

The component parts of other intangible assets at October 31, 2020 and 2021 are shown in the table below:


	Other Intangible Assets
	Gross Carrying Amount		Accumulated Amortization		Net Book Value
	(in millions)
As of October 31, 2020:
Purchased technology	$	1,429	$	863	$	566

Trademark/Tradename	196		117		79
Customer relationships	330		158		172
Third-party technology and licenses	11		7		4
Total amortizable intangible assets	$	1,966	$	1,145	$	821
In-Process R&D	10		—		10
Total	$	1,976	$	1,145	$	831
As of October 31, 2021:
Purchased technology	$	1,742	$	972	$	770
Backlog	8		3		5
Trademark/Tradename	196		133		63
Customer relationships	357		228		129
Third-party technology and licenses	11		8		3
Total amortizable intangible assets	$	2,314	$	1,344	$	970
In-Process R&D	11		—		11
Total	$	2,325	$	1,344	$	981

During fiscal year 2021, we recorded additions to goodwill of $365 million and additions to other intangible assets of $343 million with a weighted average life of 11 years related to the purchase of Resolution Bioscience. During the year other intangible assets increased $2 million due to the impact of foreign currency translation.

During fiscal year 2020, we recorded no additions to goodwill or to intangible assets. During the year ended October 31, 2020 we moved $15 million of in-process research and development intangible assets to purchased technology on the completion of three projects. The increase in other intangible assets due to foreign currency translation was not material in 2020.

In general, for United States federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible.

There were no impairments of indefinite-lived intangible assets during fiscal years 2021 and 2019. During fiscal year 2020, we recorded an impairment of in-process research and development of $90 million in research and development expenses in the consolidated statement of operations which was related to the shutdown of our sequencer development program in our diagnostics and genomics segment. During fiscal years 2021, 2020 and 2019, there were no impairments of finite-lived intangible assets recorded. During 2020, we also wrote-off the gross carrying amount of $17 million and the related accumulated amortization of fully amortized intangible assets which were no longer being used

Amortization expense of intangible assets was $195 million in 2021, $186 million in 2020, and $128 million in 2019.

Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:


Estimated future amortization expense:
	(in millions)
2022	$	191
2023	$	143
2024	$	121
2025	$	96
2026	$	66
Thereafter	$	353